<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03074032</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-ONC10013B-01</org_study_id>
    <nct_id>NCT03074032</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer</brief_title>
  <official_title>Phase I Open-label Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer (mCRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avionco LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avionco LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a PhaseI, open-label study, Dose-Escalation Study, where tolerated doses will be
      escalated to the next doses with the safety, tolerability, and PK being evaluated in
      metastatic castration-resistant prostate cancer (mCRPC) patients. Tumor assessment and PSA
      values will be evaluated during the study as an additional point.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT within 4 weeks of ONC1-0013B administration (safety and tolerability)</measure>
    <time_frame>4 weeks and during the study up to 76 weeks</time_frame>
    <description>Incidence rate and severity of adverse events, changes in laboratory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>28 days</time_frame>
    <description>PK analysis of ONC1-0013B after single and multiple dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>28 days</time_frame>
    <description>PK analysis of ONC1-0013B after single and multiple dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (T1/2)</measure>
    <time_frame>28 days</time_frame>
    <description>PK analysis of ONC1-0013B after single and multiple dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-peak concentration (tmax)</measure>
    <time_frame>28 days</time_frame>
    <description>PK analysis of ONC1-0013B after single and multiple dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-State Concentration (Css)</measure>
    <time_frame>28 days</time_frame>
    <description>PK analysis of ONC1-0013B after single and multiple dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>12 weeks and during the study up to 76 weeks</time_frame>
    <description>RECIST 1.1 criteria and the change of the PSA level</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Metastatic Castration-Resistant Prostate Cancer (mCRPC)</condition>
  <arm_group>
    <arm_group_label>ONC1-0013B 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONC1-0013B 40 mg per os daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONC1-0013B 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONC1-0013B 80 mg per os daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONC1-0013B 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONC1-0013B 160 mg per os daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONC1-0013B 320 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONC1-0013B 320 mg per os daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONC1-0013B</intervention_name>
    <description>ONC1-0013B per os daily</description>
    <arm_group_label>ONC1-0013B 40 mg</arm_group_label>
    <arm_group_label>ONC1-0013B 80 mg</arm_group_label>
    <arm_group_label>ONC1-0013B 160 mg</arm_group_label>
    <arm_group_label>ONC1-0013B 320 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men aged 18 years and older.

          2. Histologically confirmed diagnosis of prostate cancer

          3. Castrate level of testosterone in blood serum &lt; 1,7 nmol/l or &lt; 50 ng/dl

          4. PSA level at screening &gt; 2 ng/ml

          5. Progression of metastatic CRPC after the chemical castration with
             gonadotropin-releasing hormone (GnRH) analogue or after the chemical castration and
             subsequent chemotherapy.

          6. The patient's ECOG performance status of 0 - 2

          7. Patients previously treated with docetaxel chemotherapy should have received 2 or less
             prior lines of chemotherapy for mCRPC

          8. The expected survival time of not less than 12 weeks

        Exclusion Criteria:

          1. Prior anticancer therapy:

               -  Treatment with chemotherapeutic agents or radiotherapy within 4 weeks prior to
                  screening or preserved toxicities of â‰¥ II grade according to CTCAE scale, related
                  to prior anticancer therapy (excluding alopecia)

               -  Prior antiandrogen therapy: flutamide within 4 weeks prior to screening or
                  bicalutamide within 6 weeks prior to screening

               -  Exposure to bisphosphonates is allowed only if the treatment started prior to
                  screening

          2. Clinically significant cardiovascular system diseases:

          3. Clinically significant central nervous system diseases:

          4. History of other significant concomitant diseases which, in the Investigator's
             opinion, may cause a disease recurrence (i.e. uncontrolled diabetes mellitus)

          5. Prior or concomitant therapy:

               -  Exposure to drugs which may cause a convulsive state within 4 weeks prior to
                  screening

               -  Exposure to treatment with characteristics of CYP3A4 or CYP2D6 inhibitors within
                  4 weeks prior to screening

               -  Exposure to treatment relating to the Class I risk of QT-interval prolongation;
                  exposure to treatment relating to the Class II risk of QT-interval prolongation
                  is allowed if the patient have received not less than 5 half-life periods of
                  flat-dosed treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Institute of Urology and Interventional Radiology n.a. N.A. Lopatkin (branch of FSBI NMRRC of the Ministry of Health of the Russian Federation)</name>
      <address>
        <city>Moscow</city>
        <zip>105426</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Radiological Research Center n.a. A.F. Tsyb (branch of FSBI NMRRC of the Ministry of Health of the Russian Federation)</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2017</study_first_posted>
  <last_update_submitted>July 8, 2017</last_update_submitted>
  <last_update_submitted_qc>July 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

